A ranar 29 ga Yuni, 2017, ci gaban Laipushutai, aji na ƙwararrun likitanci tare da haɓaka haɗin gwiwar JYMed da Guangzhou Linkhealth Medical Technology Co., Ltd., ya sami ci gaba sosai. CFDA ta karɓi sanarwar IND na miyagun ƙwayoyi.

JYMed da Guangzhou Linkhealth Medical Technology Co., Ltd. sun cimma yarjejeniyar hadin gwiwa a cikin 2016 don haɓaka wannan samfurin tare a kasar Sin. Jinsunan sun kammala karatun POC na asibiti a cikin EU kuma sun sami kyakkyawan aminci da ƙimar gafara. Dukansu FDA da EMA sun gane cewa ana iya amfani da wannan nau'in don magani a kan layin I / II, kuma za a ba da fifiko ga taimako da kuma kula da marasa lafiya tare da matsakaicin ulcerative colitis a cikin gwaje-gwajen asibiti na CFDA.

Ulcerative colitis (UC) cuta ce ta yau da kullun, wacce ba ta musamman wacce ke faruwa a cikin dubura da hanji. Dangane da kididdigar, adadin abubuwan da suka faru na UC shine 1.2 zuwa 20.3 lokuta / mutum 100,000 a kowace shekara kuma yawancin UC shine 7.6 zuwa 246.0 lokuta / mutane 10,000 a shekara. Abubuwan da ke faruwa na UC sun fi yawa a cikin samari. Kasuwar UC tana da babban sikeli da buƙatun magunguna, kuma za ta ci gaba da kiyaye haɓakar haɓakar haɓakawa a nan gaba. Ya zuwa yanzu, maganin farko na UC ya dogara ne akan mesalazine da hormones, kuma magungunan layi na biyu sun haɗa da rigakafi da ƙwayoyin rigakafi na monoclonal na halitta. Mesalazine yana da adadin tallace-tallace na biliyan 1 a China da dala biliyan 2 a Amurka a cikin 2015. Laipushutai yana da mafi kyawun amsa ga alamun UC, kuma ya fi aminci fiye da magungunan farko na yanzu. Yana da fa'idar kasuwa mai kyau kuma ana tsammanin ya zama magungunan UC na farko.